Multiple hemp companies have filed federal lawsuits challenging the Drug Enforcement Administration's classification of hexahydrocannabinol (HHC) as an illegal Schedule I controlled substance, a fight over how the government treats synthetic cannabinoids made from hemp.
The DEA issued a rule in December declaring that HHC, a cannabinoid produced synthetically from cannabis plant components, falls under federal prohibition despite being marketed as a legal hemp derivative. The agency said it had already considered the compound illegal under the Controlled Substances Act and that the rule formalized that position.
The suits are the latest clash between the growing hemp industry and federal regulators over the boundaries set by the 2018 Farm Bill, which legalized hemp and its derivatives containing less than 0.3% delta-9 THC.
The legal arguments
The companies argue HHC qualifies as a legal hemp derivative under the Farm Bill. Because the compound can be synthesized from CBD, itself a legal hemp cannabinoid, they say it falls within the statute's protections for "all derivatives, extracts, cannabinoids" from hemp.
The DEA disagrees. In its view, synthetically produced cannabinoids are controlled substances no matter what they are made from. The agency draws the line between naturally occurring hemp compounds and those created through chemical synthesis.
That distinction matters for the estimated $28 billion hemp industry, where companies have increasingly turned to alternative cannabinoids like HHC, delta-8 THC and THC-O as legal substitutes for traditional cannabis products in states without adult-use programs.
Market impact
HHC products have spread across retail shelves and online marketplaces over the past two years, with manufacturers touting effects similar to delta-9 THC from a compound they say is federally legal. Industry estimates put the alternative cannabinoid market at about $2 billion in 2023.
Several major hemp retailers pulled HHC products from their inventories after the DEA's announcement. Others are still selling while the court challenges play out, leaving retailers, manufacturers and consumers unsure which products comply with federal law.
Trade groups including the U.S. Hemp Roundtable have warned that the DEA's broad reading could reach beyond HHC to other hemp-derived cannabinoids, threatening the entire alternative cannabinoid market that emerged after 2018.
What happens next
The lawsuits will likely take months or years to resolve in federal court. The hemp companies are seeking preliminary injunctions to block DEA enforcement while the cases proceed.
Courts have generally deferred to the DEA on classifying controlled substances, legal experts note, but the Farm Bill's explicit legalization of hemp derivatives raises questions the courts have not settled. The cases could come down to how judges read the Farm Bill against the Controlled Substances Act.
States are not waiting. Colorado, Oregon and New York have all restricted HHC and similar compounds through state legislation, adding a layer of state rules on top of the federal dispute.
The outcome will decide whether hemp companies can keep developing and selling synthetic cannabinoids, or whether the DEA's interpretation closes off that market despite the Farm Bill's hemp provisions.
This article is based on original reporting by www.marijuanamoment.net.
